On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC).
At LUNGevity, we say that our people are our most valuable asset, and our dedicated volunteers exemplify this. Hundreds of volunteers from across the country support LUNGevity and the community we serve. Volunteers use their unique talents and perspectives to provide peer support, raise awareness for lung cancer, plan events and fundraisers, and advocate.
For people with lung cancer, one of the first steps in navigating their diagnosis comes from understanding what their lung cancer stage means for the future of their treatment.
Caregiving may be the most challenging role a person can take on, but also one of the most valuable. In some instances, providing physical and emotional care to a loved one can become a round-the-clock job that may shift other priorities like career or relationships.
On February 10, 2022, the Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Decision to expand reimbursement for lung cancer screening with low-density computed tomography (LDCT).
Personalized medicine, in which the molecular profile of each patient’s tumor helps customize the course of treatment, has been useful in treating many types of cancer, including non-small cell lung cancer (NSCLC). However, for patients diagnosed with extensive small cell lung cancer (SCLC), the treatment plans are mostly one size fits all.